Patent · US Active

FIXaxFX bispecific antibody with common light chain

US10815308B2 · kind B2 · utility

2Cited by

2References

17Claims

0Family size

Assignee

KYMAB LIMITED · GB

Inventors

Wei Wang · Cambridge, GB
E-Chiang Lee · Cambridge, GB
John Kenneth Blackwood · Cambridge, GB
Roberto Magliozzi · Cambridge, GB

Key dates

Filing date	Dec 20, 2019
Grant date	Oct 27, 2020
Priority date	—
Expiry date	Dec 20, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.